Inogen Inc. (INGN)

173.62
2.20 1.30
NASDAQ : Health Technology
Prev Close 171.45
Open 171.49
Day Low/High 171.49 / 175.70
52 Wk Low/High 86.89 / 189.76
Volume 116.37K
Avg Volume 175.90K
Exchange NASDAQ
Shares Outstanding 21.22M
Market Cap 3.76B
EPS 1.00
P/E Ratio 147.58
Div & Yield N.A. (N.A)

Latest News

Inogen Announces Participation In 17th Annual Needham Healthcare Conference

Inogen Announces Participation In 17th Annual Needham Healthcare Conference

Inogen, Inc. (NASDAQ: INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, today announced that the Company's management will be participating in the 17 th...

Inogen Announces Fourth Quarter And Full Year 2017 Financial Results And Updates 2018 Guidance

Inogen Announces Fourth Quarter And Full Year 2017 Financial Results And Updates 2018 Guidance

Inogen, Inc. (NASDAQ: INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, today reported financial results for the three-month and twelve-month periods ended...

Inogen To Announce Fourth Quarter And Full Year 2017 Financial Results On Tuesday, February 27, 2018

Inogen To Announce Fourth Quarter And Full Year 2017 Financial Results On Tuesday, February 27, 2018

Inogen, Inc. (Nasdaq: INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, announced that it will release fourth quarter and full year 2017 financial results...

Inogen Announces Participation In Upcoming Leerink Partners 7th Annual Global Healthcare Conference

Inogen Announces Participation In Upcoming Leerink Partners 7th Annual Global Healthcare Conference

Inogen, Inc. (NASDAQ: INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, today announced that the Company's management will be participating in the Leerink...

Inogen Announces Participation In Upcoming J.P. Morgan Healthcare Conference & Needham Growth Conference

Inogen Announces Participation In Upcoming J.P. Morgan Healthcare Conference & Needham Growth Conference

Inogen, Inc. (NASDAQ: INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, today announced that the Company's management will be participating in the 36 th...

Inogen Announces Participation In 29th Annual Piper Jaffray Healthcare Conference

Inogen Announces Participation In 29th Annual Piper Jaffray Healthcare Conference

Inogen, Inc. (NASDAQ: INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, today announced that the Company's management will be participating in the 29th...

Inogen Recognized As One Of The Fastest Growing Companies In North America According To Deloitte's 2017 Technology Fast 500™

Inogen Recognized As One Of The Fastest Growing Companies In North America According To Deloitte's 2017 Technology Fast 500™

Inogen, Inc. (NASDAQ: INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, today announced it was included on Deloitte's Technology Fast 500™, a ranking...

Inogen Announces Record Third Quarter 2017 Financial Results

Inogen Announces Record Third Quarter 2017 Financial Results

Inogen, Inc. (NASDAQ: INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, today reported financial results for the three-month period ended September 30,...

Inogen Reaches Analyst Target Price

Inogen Reaches Analyst Target Price

In recent trading, shares of Inogen, Inc have crossed above the average analyst 12-month target price of $100.80, changing hands for $101.17/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuation, or, re-adjust their target price to a higher level.

Inogen To Announce Third Quarter 2017 Results On Tuesday, November 7, 2017

Inogen To Announce Third Quarter 2017 Results On Tuesday, November 7, 2017

Inogen, Inc. (Nasdaq: INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, announced that it will release its financial results for the third quarter of 2017...

International Paper, Inogen, Teva Pharmaceuticals: 'Mad Money' Lightning Round

International Paper, Inogen, Teva Pharmaceuticals: 'Mad Money' Lightning Round

Jim Cramer likes International Paper and Inogen, but he's bearish on Teva Pharmaceuticals.

Fantasy Football and Picking Stocks: Cramer's 'Mad Money' Recap (Tues 8/15/17)

Fantasy Football and Picking Stocks: Cramer's 'Mad Money' Recap (Tues 8/15/17)

Jim Cramer says a well-diversified portfolio is a lot like a well-balanced and winning football team.

Inogen Announces Record Second Quarter 2017 Financial Results

Inogen Announces Record Second Quarter 2017 Financial Results

Inogen, Inc. (NASDAQ: INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, today reported financial results for the three-month period ended June 30, 2017.

Inogen To Announce Second Quarter 2017 Results On Thursday, August 3, 2017

Inogen To Announce Second Quarter 2017 Results On Thursday, August 3, 2017

Inogen, Inc. (Nasdaq: INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, announced that it will release its financial results for the second quarter of 2017...

Inogen Secures Additional Facility To Support Direct-to-Consumer Sales Growth

Inogen, Inc. (NASDAQ: INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, today announced that it has secured an additional facility in the Cleveland, OH...

Inogen Broadens Market Access For Innovative Portable Oxygen Concentrator

Inogen, Inc. (NASDAQ: INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, today announced that it has received the EC Certificate for the Inogen One G4...

Inogen Announces Participation In 37th Annual William Blair Growth Stock Conference

Inogen, Inc. (NASDAQ: INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, today announced that the Company's management will be participating in the 37th...

INGN Crosses Above Average Analyst Target

In recent trading, shares of Inogen, Inc have crossed above the average analyst 12-month target price of $84.83, changing hands for $85.27/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuation, or, re-adjust their target price to a higher level.

Inogen Announces First Quarter 2017 Financial Results

Inogen, Inc. (NASDAQ: INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, today reported financial results for the three-month period ended March 31, 2017.

Inogen To Announce First Quarter 2017 Results On Tuesday, May 9, 2017

Inogen, Inc. (Nasdaq: INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, announced that it will release its financial results for the first quarter of 2017...

Inogen Announces Participation In 16th Annual Needham Healthcare Conference

Inogen, Inc. (NASDAQ: INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, today announced that the Company's management will be participating in the 16th...

Inogen Reaches Analyst Target Price

In recent trading, shares of Inogen, Inc have crossed above the average analyst 12-month target price of $76.20, changing hands for $76.44/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuation, or, re-adjust their target price to a higher level.

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,200 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: ALEX, AZN, BDL, INGN, ITRI, PAH Downgrades: AGYS, ASFI, IKNX, PRFT, SIX, VNCE Initiations: SRG Read on to get TheStreet Quant Ratings' detailed report:

Inogen Announces Fourth Quarter And Full Year 2016 Financial Results And Updates 2017 Guidance

Inogen, Inc. (NASDAQ: INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, today reported financial results for the three-month and twelve-month periods ended...

Inogen Reaches Analyst Target Price

In recent trading, shares of Inogen, Inc have crossed above the average analyst 12-month target price of $69.00, changing hands for $69.21/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuation, or, re-adjust their target price to a higher level.

Inogen To Announce Fourth Quarter And Full Year 2016 Results On Tuesday, February 28, 2017

Inogen, Inc. (Nasdaq: INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, announced that it will release its financial results for the fourth quarter and full...

Inogen To Participate In Upcoming Investor Conferences

Inogen, Inc. (NASDAQ: INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, today announced that the Company's management will be participating in two upcoming...

Inogen Provides Impact From 21st Century Cures Act

Inogen Provides Impact From 21st Century Cures Act

Inogen, Inc. (NASDAQ: INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, today announced the estimated impact of the 21 st Century Cures Act to its 2016...

TheStreet Quant Rating: B (Buy)